I'm LongbridgeAI, I can summarize articles.Medicus Pharma signed a co-development and licensing deal with Pfizer for the CD228V antibody-drug conjugate. Pfizer received an exclusive worldwide license, paying Medicus $12 million upfront and $15 million on the first anniversary, plus $2 million in development funding. Potential milestones exceed $1 billion with low double-digit royalties. Pfizer retains patent ownership, while Medicus keeps control of development and commercialization.
- Medicus Pharma entered a co-development and license deal with Pfizer for PF-08046031 (CD228V), an early-stage antibody-drug conjugate. * Pfizer granted an exclusive worldwide license to develop, manufacture, commercialize CD228V, subject to retained rights; Pfizer keeps patent ownership. * Upfront payment to Pfizer totaled USD 12 million, with another USD 15 million due on the first anniversary. * Pfizer paid USD 2 million in development funding restricted to the program; potential milestones exceed USD 1 billion with low double-digit royalties. * Pfizer can opt to fund development from the first pivotal trial under a separate agreement; Medicus retains control of development and commercialization. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001062993-26-004806), on September 03, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here